@article{fdi:010080509,
  title = {{HPV} cervical infections and serological status in vaccinated and unvaccinated women},
  author = {{M}urall, {C}. {L}. and {R}eyne, {B}. and {S}elinger, {C}hristian and {B}ernat, {C}. and {B}oue, {V}. and {G}rasset, {S}. and {G}roc, {S}. and {R}ahmoun, {M}. and {B}ender, {N}. and {B}onneau, {M}. and {F}oulongne, {V}. and {G}raf, {C}. and {P}icot, {E}. and {P}icot, {M}. {C}. and {T}ribout, {V}. and {W}aterboer, {T}. and {B}ravo, {I}. {G}. and {R}eynes, {J}. and {S}egondy, {M}. and {B}oulle, {N}. and {A}lizon, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{U}nderstanding genital infections by {H}uman papillomaviruses ({HPV}s) remains a major public health issue, especially in countries where vaccine uptake is low. {W}e investigate {HPV} prevalence and antibody status in 150 women (ages 18 to 25) in {M}ontpellier, {F}rance. {A}t inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. {O}ncogenic, non-vaccine genotypes {HPV}51, {HPV}66, {HPV}53, and {HPV}52 were the most frequently detected viral genotypes overall. {V}accination status, which was well-balanced in the cohort, showed the strongest (protective) effect against {HPV} infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). {W}e also identified significant effects of age, number of partners, body mass index, and contraception status on {HPV} detection and on coinfections. {T}ype-specific {I}g{G} serological status was also largely explained by the vaccination status. {I}g{M} seropositivity was best explained by {HPV} detection at inclusion only. {F}inally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of {HPV}51 in vaccinated women. {V}ariations in {HPV} prevalence correlate with key demographic and behavioural variables. {T}he cross-protective effect of the vaccine against {HPV}51 merits further investigation.},
  keywords = {{HPV} ; {V}accination ; {S}erology ; {C}ross-protection ; {A}cute infections ; {G}enital infections ; {FRANCE}},
  booktitle = {},
  journal = {{V}accine},
  volume = {38},
  numero = {51},
  pages = {8167--8174},
  ISSN = {0264-410{X}},
  year = {2020},
  DOI = {10.1016/j.vaccine.2020.10.078},
  URL = {https://www.documentation.ird.fr/hor/fdi:010080509},
}